Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b <scp>OCARINA</scp> I study
Scott D. Newsome(Johns Hopkins University), Robert A Bermel(Cleveland Clinic), Oscar Bortolami(Statistics Korea), Susanne Clinch(Université de Bordeaux), Lawrence Goldstick(University of Cincinnati), M Giraudon(Roche (Switzerland)), Gurpreet Deol‐Bhullar(Roche (Canada)), Derrick Robertson(University of South Florida), James D. Bowen(Swedish Medical Center), Robert T. Naismith(Washington University in St. Louis), Caroline Giacobino(Roche (Switzerland)), Dusanka Zecevic(Roche (Switzerland)), Catarina Figueiredo(Roche (Switzerland)), Ben Townsend(Roche (Switzerland)), Yun‐An Shen(Sunesis (United States)), Heidemarie Kletzl(Roche (Switzerland))
Cited by 3
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Dementia and Alzheimer Disease Incidence
|Archives of Neurology|2002|797
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
|The Lancet Neurology|2021|646
How patients with multiple sclerosis acquire disability
|Brain|2022|532
Performance-Based Physical Function and Future Dementia in Older People
|Archives of Internal Medicine|2006|327